Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs. #EULAR2026 @RheumNow https://t.co/JmTSC1uaph

#Vaccination in Rheum 📍Hold MTX 1-2wks post vax 📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals. THM: Assess vax need at dx, vax w/o delay #EULAR2026 @RheumNow https://t.co/6ptl8gyBLR

#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16. -Improvement as early as Week 4 -Low viral infections. Common AE: nasopharyngitis & headache. -Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi

#EULAR2026 Still undecided which session to attend? Please find my Conference Preview in the field of #SLE #lupus #biologics #targetedtherapy @RheumNow 😃 https://t.co/0m2p8mEgCQ https://t.co/C3xa5rPp9q

#EULAR2026 General Assembly is ON! Record-breaking 5'705 abstracts from 102 countries 187 scientific sessions ahead @rheumnow https://t.co/0kAqND11L7

Applying updated ACR guidelines in real life isn’t always straightforward. Two experts share insights on managing lupus nephritis beyond the textbook. Sponsored by Aurinia https://t.co/7NAJW3LoSM https://t.co/h5RHK290pD

Advanced Practice Rheum: Safety of Biologics and Novel Agents Dr. Jack Cush reviews safety of biologics and novel agents. This video is part of the Advanced Practice Rheum series. https://t.co/K5TiwFA0L2 https://t.co/XoFsTMnxPC

DERM on RheumNow PODCAST (May 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. Dermatology drugs, biologics, JAKs - their use, efficacy, and https://t.co/0AEAxadBFT

Count Your Telangiectasias (5.29.2026) Dr. Jack Cush reviews the news, journal articles and missed quiz questions. https://t.co/KDXijQMdfr https://t.co/2Vi3MKZZbk

RA comorbidities are changing. ILD, anxiety, depression increasing. Less extraartic. manifestations, CA & CV dz. Consider screening for cervical CA, ILD, CV dz & OP (for pts on steroids) https://t.co/WVITFXNva7 https://t.co/tggdaO9RJB

Congratulations to Professor Dennis McGonagle for being awarded the prestigious Heberden Oration Award at the 2026 British Society for Rheumatology (BSR) Conference. https://t.co/TOG5Y9tNrW https://t.co/3aumO6Z3A9

Curcumin in arthritis may have NSAID like clinical efficacy. But how? Metanalysis lays out the multiple potential effects for it to inhibit inflammatory signaling pathways (NF-κB, TNF-α, IL-1β, IL-6, COX-2, and PGE2) https://t.co/gSYVwpl41P https://t.co/0xZdyiF4QN

Increased Polypharmacy in SLE Patients A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications. https://t.co/3Mo3O8Ra04 https://t.co/zRS8TmFvvf